Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thailanstatin D is a potent cytotoxic natural product belonging to the thailanstatin family, originally isolated from the bacterium *Burkholderia thailandensis*. It functions as a spliceosome inhibitor by specifically targeting the SF3b (Splicing Factor 3b) complex, which is essential for the recognition of the branch point sequence during pre-mRNA splicing. By disrupting the splicing process, thailanstatin D induces cell cycle arrest and apoptosis in cancer cells. Due to its high potency and distinct mechanism of action compared to traditional tubulin or DNA-targeting agents, it is primarily utilized as a payload for antibody-drug conjugates (ADCs). Shanghai Minbiotech serves as a commercial supplier and manufacturer of this compound for pharmaceutical research and development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thailanstatin D.